SUBSCRIBE
SUBSCRIBE

Shattuck Labs

NEWS
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Shattuck Labs to Lay Off 40% of Workforce
As it shifts focus to a death receptor 3 (DR3) antagonist antibody, Shattuck Labs is cutting a significant number of employees before the end of the year.
October 1, 2024
 · 
2 min read
 · 
Angela Gabriel
Deals
4 Biotech IPOs this Week: Kronos, Shattuck, Spruce and Aziyo
It’s been a fairly busy week for biotech initial public offerings (IPOs) with four announcing their list pricing. Here’s a look.
October 9, 2020
 · 
4 min read
 · 
Mark Terry
JOBS
IN THE PRESS
Bio NC
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
 · 
1 min read
Bio NC
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
December 21, 2023
 · 
4 min read
Drug Development
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154
December 13, 2023
 · 
10 min read
Drug Development
Shattuck Labs to Host Investor Call & Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline HR-MDS and TP53m AML and Review of Dose-Escalation Data from the ASH 2023 Annual Meeting on December 13, 2023
December 5, 2023
 · 
1 min read
Bio NC
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
November 14, 2023
 · 
1 min read
Business
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 9, 2023
 · 
15 min read
Business
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
November 6, 2023
 · 
1 min read
Drug Development
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the ASH 2023 Annual Meeting
November 2, 2023
 · 
8 min read
Business
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023
 · 
12 min read
Drug Development
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
May 25, 2023
 · 
7 min read
Load More